Rasna Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Rasna Therapeutics generated cash of -$8,516, which is more than the previous year. Cash used in financing activities reached the amount of $44,139 last year. Net change in cash is therefore $35,623.
Cash Flow
| 2014 | -40.01K | 0 | 0 |
|---|---|---|---|
| 2015 | -12.93K | 0 | 6.63K |
| 2016 | -11.46K | 0 | 11.55K |
| 2017 | -2.96M | 5.10M | 2.00M |
| 2018 | -2.62M | -4.07K | 135K |
| 2019 | -92.62K | 0 | 100K |
| 2020 | -251.32K | 0 | 215.5K |
| 2021 | -293.39K | 0 | 290K |
| 2022 | -312.66K | 0 | 341.17K |
| 2023 | -8.51K | 0 | 44.13K |
RASP Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 39.36K | 10.84K | 14.24K | 50.06K | 42.69K | 2.53M | 134 | 35 | 6.33K | 46.34K |
Operating activities | ||||||||||
Net income | -4.44M | -686.58K | -785.08K | -5.34M | -936.38K | -4.07M | -4.43M | -62.22K | -16.75K | -40.03K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 314 | 1.63K | 3.47K | 4.83K | 3.46K | 0 | 0 | 0 |
Stock-based compensation expense | 0 | 0 | 42.67K | 134.63K | 368.07K | 0 | 1.02M | 0 | 117.30K | 0 |
| Deferred income tax benefit | 0 | 0 | 42.67K | 134.63K | 368.07K | 0 | 1.02M | 0 | 117.30K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 748 | 2.51K | 283.29K | 0 | 46.98K | 0 | 1.81M | 0 |
Inventories | 0 | 0 | -748 | -2.51K | -283.29K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 106.89K | -14.68K | -119.78K | 45.19K | 168.93K | 439.72K | 519.11K | 0 | 3.82K | 375 |
Cash generated by operating activities | -8.51K | -312.66K | -293.39K | -251.32K | -92.62K | -2.62M | -2.96M | -11.46K | -12.93K | -40.01K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | -4.07K | -10.49K | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 5.11M | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | -4.07K | 5.10M | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 3.85M | 0 | 0 | 0 | 0 | 0 | 2.00M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 44.13K | 341.17K | -290K | -215.5K | 100K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 44.13K | 341.17K | 290K | 215.5K | 100K | 135K | 2.00M | 11.55K | 6.63K | 0 |
Net Change In Cash | 35.62K | 28.51K | -3.39K | -35.82K | 7.37K | -2.49M | 4.04M | 99 | -6.3K | -40.01K |
Cash at end of period | 74.98K | 39.36K | 10.84K | 14.24K | 50.06K | 42.69K | 4.04M | 134 | 35 | 6.33K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |